Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 4
2006 2
2007 6
2008 15
2009 29
2010 21
2011 35
2012 39
2013 33
2014 42
2015 47
2016 43
2017 38
2018 63
2019 86
2020 99
2021 106
2022 101
2023 115
2024 40

Text availability

Article attribute

Article type

Publication date

Search Results

859 results

Results by year

Filters applied: . Clear all
Page 1
Natural variation of Dt2 determines branching in soybean.
Liang Q, Chen L, Yang X, Yang H, Liu S, Kou K, Fan L, Zhang Z, Duan Z, Yuan Y, Liang S, Liu Y, Lu X, Zhou G, Zhang M, Kong F, Tian Z. Liang Q, et al. Among authors: fan l. Nat Commun. 2022 Oct 28;13(1):6429. doi: 10.1038/s41467-022-34153-4. Nat Commun. 2022. PMID: 36307423 Free PMC article.
An overview of PROTACs: a promising drug discovery paradigm.
Liu Z, Hu M, Yang Y, Du C, Zhou H, Liu C, Chen Y, Fan L, Ma H, Gong Y, Xie Y. Liu Z, et al. Among authors: fan l. Mol Biomed. 2022 Dec 20;3(1):46. doi: 10.1186/s43556-022-00112-0. Mol Biomed. 2022. PMID: 36536188 Free PMC article. Review.
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM. Yu KD, et al. Among authors: fan l. JAMA Oncol. 2020 Sep 1;6(9):1390-1396. doi: 10.1001/jamaoncol.2020.2965. JAMA Oncol. 2020. PMID: 32789480 Free PMC article. Clinical Trial.
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, Yu KD, Fan L, Li JJ, Hou YF, Hu Z, Chen CM, Huang XY, Cao AY, Hu X, Zhao S, Ma XY, Xu Y, Sun XJ, Chai WJ, Guo X, Chen X, Xu Y, Zhu XY, Zou JJ, Yang WT, Wang ZH, Shao ZM. Chen L, et al. Among authors: fan l. Clin Cancer Res. 2022 Jul 1;28(13):2807-2817. doi: 10.1158/1078-0432.CCR-21-4313. Clin Cancer Res. 2022. PMID: 35247906 Free PMC article.
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Fan L, Wang ZH, Ma LX, Wu SY, Wu J, Yu KD, Sui XY, Xu Y, Liu XY, Chen L, Zhang WJ, Jin X, Xiao Q, Shui RH, Xiao Y, Wang H, Yang YS, Huang XY, Cao AY, Li JJ, Di GH, Liu GY, Yang WT, Hu X, Xia Y, Liang QN, Jiang YZ, Shao ZM. Fan L, et al. Lancet Oncol. 2024 Feb;25(2):184-197. doi: 10.1016/S1470-2045(23)00579-X. Epub 2024 Jan 8. Lancet Oncol. 2024. PMID: 38211606 Clinical Trial.
859 results